Buy ABOS: Speculative Play for the November ALTITUDE-AD Readout
Acumen Pharmaceuticals (ABOS) is a high-risk, high-reward trade ahead of topline Phase 2 ALTITUDE-AD results expected in November. The company has 542 patients enrolled, management is targeting a 30% slowing on iADRS as the success benchmark, and Q3 burn and cash position imply a compressed runway. With a $173M market cap, meaningful short interest…